Clinical Trials Logo

Clinical Trial Summary

To compare the complete cytogenetic response rate in patients with newly-diagnosed chronic-phase chronic myeloid leukaemia treated with Glivec® alone or in combination with interferon at low doses


Clinical Trial Description

Open, prospective, multicentre, phase IV, comparative and randomised study ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00390897
Study type Interventional
Source PETHEMA Foundation
Contact
Status Completed
Phase Phase 4
Start date July 2003
Completion date December 2007

See also
  Status Clinical Trial Phase
Completed NCT01475110 - Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib
Recruiting NCT05682924 - Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib
Completed NCT05286528 - Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
Completed NCT01597219 - Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers Phase 2
Active, not recruiting NCT01699217 - Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
Completed NCT02546375 - A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands
Active, not recruiting NCT01804985 - De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia Phase 2
Completed NCT01343173 - Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib N/A
Completed NCT05893836 - Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia
Recruiting NCT02001818 - Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia Phase 2
Completed NCT01621724 - WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study Phase 1/Phase 2